Skip to content

Comparison the effect of L-carnitine versus placebo on control of Attention deficit-hyper activity disorder symptoms

Comparison the effect of L-carnnitine versus placebo on control of attention deficit-hyper activity disorder symptoms in Iranian children and adolescents, a double blind randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013090914598N1
Enrollment
36
Registered
2013-09-20
Start date
2013-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit-hyperactivity disorder. Disturbance of activity and attention

Interventions

Intervention 1: Intervention group will receive 50 mg/kg/day of L-carnitine syrup (product of shahr Darou company which contains 1g/10cc of drug) in divided dose,BID,morning and afternoon except takin
Treatment - Drugs
Placebo
Intervention group will receive 50 mg/kg/day of L-carnitine syrup (product of shahr Darou company which contains 1g/10cc of drug) in divided dose,BID,morning and afternoon except taking Methylphenida
Control group will receive 50 mg/kg/day of placebo ( Sucrose solution in the same package and same dilution asL-carnitine syrup)BID,morning and afternoon except taking their Methylphenidate tablet.

Sponsors

Vice chancellor for Research Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Age 6-16; Diagnosis of ADHD for the first time Exclusion criteria : IQ<70 ; Having other chronic medical illnesses; Be under other medications; Any serious or sever complication during study; Refusal of child or parent to continue the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Attention, Impulsivity & Behavioral indecies. Timepoint: At the begining,3 weeks later & 6 weeks later. Method of measurement: Conner's parents questionaire.

Secondary

MeasureTime frame
Child's general function. Timepoint: At the begining of study , 3 weeks later , 6 weeks later. Method of measurement: CGAS questionare.;Drug complication. Timepoint: 3 weeks after begining of the study & 6 weeks later. Method of measurement: Rachell & klein Side effects Form.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fateme Noori

Tehran Institute of Psychiatry

noori_fatm@yahoo.com+98 21 6655 1515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026